IP Library Granted Patent US 12,458,573
Granted Patent B2
US 12,458,573 · App. 17/196,886 · Granted Nov 4, 2025

Surfactants for personal care and cosmetic products

Inventor: Edward Asirvatham (Chatham, NJ)
Assignee: AdvanSix Resins & Chemicals LLC.
A61K8/416A61K8/046A61K8/41A61K8/965A61Q5/02A61Q5/12A61Q11/00A61Q19/10A61K2800/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,573
App. No.
17/196,886
Granted
Nov 4, 2025
Kind
B2
Abstract

Personal care products, such as shampoos, conditioners, hair dyes, hair removal products, cleansers, cosmetics, mascaras, and toothpastes may be formulated to include one or more surfactants, from one or more surfactant classes, such as derivatives of amino acids that have surface-active properties.

Claims (64)

1 . A formulation for a shampoo, comprising:

at least one surfactant of Formula I,

wherein R 1 and R 2 may be the same or different, and may be selected from the group consisting of hydrogen and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;

n is 5;

m is an integer from 9 to 20 (including 9 and 20);

the terminal nitrogen is optionally further substituted with R 3 wherein R 3 is selected from the group consisting of hydrogen, oxygen, hydroxyl, and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;

an optional counterion associated with the compound which, if present, is selected from the group consisting of bromide, iodide, and hydroxide;

wherein the surfactant of Formula I is a cationic surfactant or a nonionic surfactant;

at least one of a foaming agent, a foam booster, and a thickener;

and water.

2 . The formulation of claim 1 , further comprising a pH stabilizer.

3 . The formulation of claim 1 , further comprising a fragrance.

4 . The formulation of claim 1 , wherein the surfactant comprises at least one of 6-(dodecyloxy)-N,N,N-trimethyl-6-oxohexan-1-aminium iodide, having the following formula:

dodecyl 6-(dimethylamino)hexanoate N-oxide, having the following formula:

and

combinations thereof.

5 . A formulation for a hair conditioner, comprising:

at least one surfactant of Formula I,

wherein R 1 and R 2 may be the same or different, and may be selected from the group consisting of hydrogen and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;

n is 5;

m is an integer from 9 to 20 (including 9 and 20);

the terminal nitrogen is optionally further substituted with R 3 , wherein R 3 is selected from the group consisting of hydrogen, oxygen, hydroxyl, and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;

an optional counterion associated with the compound which, if present, is selected from the group consisting of bromide, iodide, and hydroxide;

wherein the surfactant of Formula I is a cationic surfactant or a nonionic surfactant;

at least one of a fatty component and an emulsifier; and

water.

6 . The formulation of claim 5 , further comprising at least one thickening agent.

7 . The formulation of claim 5 , further comprising a foaming agent.

8 . The formulation of claim 5 , further comprising at least one clay.

9 . The formulation of claim 5 , further comprising a fragrance.

10 . The formulation of claim 5 , wherein the surfactant comprises at least one of 6-(dodecyloxy)-N,N,N-trimethyl-6-oxohexan-1-aminium iodide, having the following formula:

dodecyl 6-(dimethylamino)hexanoate N-oxide, having the following formula:

combinations thereof.

11 . A formulation for a cleanser, comprising:

at least one surfactant of Formula I,

wherein R 1 and R 2 may be the same or different, and may be selected from the group consisting of hydrogen and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;

n is 5;

m is an integer from 9 to 20 (including 9 and 20);

the terminal nitrogen is optionally further substituted with R 3 , wherein R 3 is selected from the group consisting of hydrogen, oxygen, hydroxyl, and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;

an optional counterion associated with the compound which, if present, is selected from the group consisting of bromide, iodide, and hydroxide;

wherein the surfactant of Formula I is a cationic surfactant or a nonionic surfactant;

at least one of a solvent, a water-soluble polymer, and a humectant; and water.

12 . The formulation of claim 11 , further comprising a fatty component.

13 . The formulation of claim 11 , further comprising at least one conditioner.

14 . The formulation of claim 11 , further comprising a hydrophobicity modifier.

15 . The formulation of claim 11 , wherein the surfactant comprises at least one of 6-(dodecyloxy)-N,N,N-trimethyl-6-oxohexan-1-aminium iodide, having the following formula:

dodecyl 6-(dimethylamino)hexanoate N-oxide, having the following formula:

and

combinations thereof.

16 . A formulation for a toothpaste, comprising:

at least one surfactant of Formula I,

wherein R 1 and R 2 may be the same or different, and may be selected from the group consisting of hydrogen and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;

n is 5;

m is an integer from 9 to 20 (including 9 and 20);

the terminal nitrogen is optionally further substituted with R 3 , wherein R 3 is selected from the group consisting of hydrogen, oxygen, hydroxyl, and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl may optionally be substituted with one or more substituents selected from the group consisting of hydroxyl, amino, amido, sulfonyl, sulfonate, carbonyl, carboxyl, and carboxylate;

an optional counterion associated with the compound which, if present, is selected from the group consisting of bromide, iodide, and hydroxide;

wherein the surfactant of Formula I is a cationic surfactant or a nonionic surfactant;

at least one of fluoride ion source and calcium carbonate; and

water.

17 . The formulation of claim 16 , further comprising at least one basic amino acid.

18 . The formulation of claim 16 , further comprising a flavoring agent.

19 . The formulation of claim 16 , wherein the surfactant comprises at least one of 6-(dodecyloxy)-N,N,N-trimethyl-6-oxohexan-1-aminium iodide, having the following formula:

dodecyl 6-(dimethylamino)hexanoate N-oxide, having the following formula:

and combinations thereof.

Assignments (2)
SECURITY INTEREST Recorded Oct 27, 2021
From: ADVANSIX INC.; ADVANSIX RESINS & CHEMICALS LLC
To: TRUIST BANK, AS ADMINISTRATIVE AGENT
Reel/Frame 057940/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2021
From: ASIRVATHAM, EDWARD
To: ADVANSIX RESINS & CHEMICALS LLC
Reel/Frame 056334/0499 →
Continuity (2)
Provisional Application 62988201 · Mar 11, 2020
Related Publication 20210283030A1 · Sep 16, 2021
References Cited (92)
US 3213500A · Thompson · 1965 [cited by applicant]
US 3704486A · Blacklock · 1972 [cited by applicant]
US 4276460A · Haesly et al. · 1981 [cited by applicant]
US 4297769A · Coules · 1981 [cited by applicant]
US 4502193A · Harmon et al. · 1985 [cited by applicant]
US 4664458A · Worth · 1987 [cited by applicant]
US 5060100A · Mihara et al. · 1991 [cited by applicant]
US 5500208A · Charbonneau · 1996 [cited by examiner]
US 5580203A · Read et al. · 1996 [cited by applicant]
US 5706559A · Oliver et al. · 1998 [cited by applicant]
US 5798095A · Racky · 1998 [cited by applicant]
US 5958894A · Heath et al. · 1999 [cited by applicant]
US 5972323A · Lang et al. · 1999 [cited by applicant]
US 6114757A · Delprete · 2000 [cited by applicant]
US 6304986B1 · Ma et al. · 2001 [cited by applicant]
US 6501030B1 · Parizi et al. · 2002 [cited by applicant]
US 6702592B1 · Harden et al. · 2004 [cited by applicant]
US 7646556B1 · Kose et al. · 2010 [cited by applicant]
US 7653847B1 · Liikanen et al. · 2010 [cited by applicant]
US 7768736B2 · Belmont et al. · 2010 [cited by applicant]
US 8599507B2 · Sanvido et al. · 2013 [cited by applicant]
US 8964320B1 · Hu et al. · 2015 [cited by applicant]
US 9142246B1 · Trantham et al. · 2015 [cited by applicant]
US 9484059B2 · Lim et al. · 2016 [cited by applicant]
US 9552846B1 · Lim · 2017 [cited by applicant]
US 20030081357A1 · Hong et al. · 2003 [cited by applicant]
US 20080259100A1 · Rengaswamy et al. · 2008 [cited by applicant]
US 20160108347A1 · McCarthy · 2016 [cited by examiner]
US 20170079898A1 · Fevola · 2017 [cited by examiner]
US 20170081277A1 · Boaz et al. · 2017 [cited by applicant]
US 20190010426A1 · Scialla et al. · 2019 [cited by applicant]
US 20210229053A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210230100A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210230106A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210230107A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210230108A1 · Asirvatham et al. · 2021 [cited by applicant]
US 20210284896A1 · Asirvatham · 2021 [cited by applicant]
US 20210284936A1 · Asirvatham · 2021 [cited by applicant]
US 20210289776A1 · Asirvatham · 2021 [cited by applicant]
US 20210290765A1 · Asirvatham · 2021 [cited by applicant]
US 20210292583A1 · Asirvatham · 2021 [cited by applicant]
US 20210292647A1 · Asirvatham · 2021 [cited by applicant]
CN 105802600A · 2016 [cited by applicant]
CN 108024935A · 2018 [cited by applicant]
DE 3939746A1 · 1991 [cited by applicant]
DE 29622184U1 · 1997 [cited by applicant]
EP 0638236A1 · 1995 [cited by applicant]
EP 0826661A2 · 1998 [cited by applicant]
GB 2204740A · 1988 [cited by applicant]
GB 2311033A · 1997 [cited by applicant]
JP 61278341A · 1986 [cited by applicant]
JP 04349284A · 1992 [cited by applicant]
JP 08007556A · 1996 [cited by applicant]
JP 09266021A · 1997 [cited by applicant]
JP 11233910A · 1999 [cited by applicant]
JP 2000502718A · 2000 [cited by applicant]
JP 2006294170A · 2006 [cited by applicant]
JP 2009108057A · 2009 [cited by applicant]
JP 2010144031A · 2010 [cited by applicant]
JP 2013511270A · 2013 [cited by examiner]
JP 2017195029A · 2017 [cited by applicant]
WO 9845233A2 · 1998 [cited by applicant]
WO 0368377A1 · 2003 [cited by applicant]
WO 2012061093A1 · 2012 [cited by applicant]
WO 2017012087A1 · 2017 [cited by applicant]
WO 2017048555A1 · 2017 [cited by applicant]
WO 2017199921A1 · 2017 [cited by applicant]
WO 2018115191A1 · 2018 [cited by applicant]
Subkowski ,PE2E translation of JP 2013511270 A ,Use Of Physiologically Cool Active Ingredients And Medicaments Containing Such Active Ingredients (Year: 2013). [cited by examiner]
Michal Novotný, Alexandr Hrabálek, Barbora Jan{dot over (u)}šová, Jakub Novotný, Kateřina Vávrová, Transkarbams as transdermal permeation enhancers: Effects of ester position and ammonium carbamate formation, May 2, 201… [cited by examiner]
Subkowski ,PE2E translation of JP 2013511270 A ,Use Of Physiologically Cool Active Ingredients And Medicaments Containing Such Active Ingredients (Year: 2013) (Year: 2013). [cited by examiner]
Berge S.M, Bighley L.D, Monkhouse D., Pharmaceutical Salts, Jan. 1977, Jounral of Pharmaceutical Sciences, vol. 66, No. 1 (Year: 1997). [cited by examiner]
Michal Novotný, Jana Klimentová, Barbora Jan{dot over (u)}šová, Karel Palát, Alexandr Hrabálek, Kateina Vávrová, Ammonium carbamates as highly active transdermal permeation enhancers with a dual mechanism of action. Jou… [cited by examiner]
Hrabálek et al., “Esters of omega-amino acids as flexible penetration enhancers”, Pharmazie, vol. 49, No. 5, May 1994, pp. 325-328. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/021565, mailed on Jun. 18, 2021, 13 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/021569, mailed on May 17, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/21571, mailed on Jul. 9, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/21574, mailed on Jul. 1, 2021, 10 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/21595, mailed on Jul. 30, 2021, 15 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/21596, mailed on Jun. 22, 2021, 10 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/21597, mailed on Aug. 9, 2021, 11 pages. [cited by applicant]
Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US21/21595, mailed on Jun. 9, 2021, 9 pages. [cited by applicant]
Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US21/21597, mailed on Jun. 17, 2021, 7 pages. [cited by applicant]
Kerry P. Mahon et al: “Combinatorial Approach to Determine Functional Group Effects on Lipidoid-Mediated si RNA Delivery”, Bioconjugate Chemistry, vol. 21, No. 8, Aug. 18, 2010 (Aug. 18, 2010), pp. 1448-1454. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/014440, mailed on Apr. 30, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/014444, mailed on Apr. 26, 2021, 12 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/014445, mailed on Apr. 26, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/014447, mailed on Apr. 30, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/014457, mailed on Apr. 30, 2021, 8 pages. [cited by applicant]
Novotny et al., “Transkarbams as transdermal permeation enhancers: effects of ester position and ammonium carbamate formation”, Bioorganic & medicinal chemistry letters, vol. 20, No. 9, May 1, 2010, pp. 2726-2728. [cited by applicant]
Yasa et al., “Synthesis, characterization, antimicrobial and biofilm inhibitory activities of new N-oxide esters”, Medicinal Chemistry Research, vol. 26, No. 8, Apr. 3, 2017, pp. 1689-1696. [cited by applicant]
Bordes et al., “Amino acid-based surfactants—do they deserve more attention?”, Advances in Colloid and Interface Science, 222 (2015) pp. 79-91. [cited by applicant]